YZJ-5053
/ Yangtze River Pharmaceutical Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 17, 2024
A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=157 | Recruiting | Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Metastases • New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1